WuXi XDC Cayman (STU:L74) FCF Margin % : -44.83% (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. WuXi XDC Cayman's Free Cash Flow for the six months ended in Jun. 2024 was €-95.6 Mil. WuXi XDC Cayman's Revenue for the six months ended in Jun. 2024 was €213.2 Mil. Therefore, WuXi XDC Cayman's FCF Margin % for the quarter that ended in Jun. 2024 was -44.83%.

As of today, WuXi XDC Cayman's current FCF Yield % is -2.04%.

The historical rank and industry rank for WuXi XDC Cayman's FCF Margin % or its related term are showing as below:

STU:L74' s FCF Margin % Range Over the Past 10 Years
Min: -33.24 Med: -3.7 Max: 5.09
Current: -20.81

During the past 5 years, the highest FCF Margin % of WuXi XDC Cayman was 5.09%. The lowest was -33.24%. And the median was -3.70%.

STU:L74's FCF Margin % is ranked worse than
66.35% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.33 vs STU:L74: -20.81

WuXi XDC Cayman FCF Margin % Historical Data

The historical data trend for WuXi XDC Cayman's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman FCF Margin % Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

-33.24

2.32

5.09

-9.72

WuXi XDC Cayman Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial			11.68	-9.88	-9.58	-44.83	-

Competitive Comparison of WuXi XDC Cayman's FCF Margin %

For the Diagnostics & Research subindustry, WuXi XDC Cayman's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi XDC Cayman's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's FCF Margin % distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's FCF Margin % falls into.

Save Embed

;

Save Embed

;

WuXi XDC Cayman FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

WuXi XDC Cayman's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-26.522	/	272.76
	=	-9.72 %

WuXi XDC Cayman's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-95.594	/	213.237
	=	-44.83 %

WuXi XDC Cayman FCF Margin % Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (STU:L74) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

02268:Hong Kong L74:Germany

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

https://www.wuxixdc.com

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman Headlines

No Headlines